FDA Extends Pain Drug Advisory Panel for Two Years
Published Date: 4/27/2026
Notice
Summary
The FDA is renewing its Anesthetic and Analgesic Drug Products Advisory Committee for two more years, keeping it active until May 1, 2028. This committee helps make sure pain and anesthesia drugs are safe and effective, especially focusing on issues like opioid abuse. The renewal means the committee will keep advising the FDA without any new costs or delays.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in